Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 172
- Registration Number
- NCT03854617
Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 1165
- Registration Number
- NCT03821441
- Locations
- 🇨🇳
Guangxi Provincial Center for Diseases Control and Prevention, Nanning, Guangxi, China
Hemodynamic Changes During Dry Cupping Therapy on Low Back Pain
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT03816787
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT03815461
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
HFSRT With Concurrent TMZ for Large BMs
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 224
- Registration Number
- NCT03778541
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 29
- Registration Number
- NCT03735082
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03731390
- Locations
- 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT03731442
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03639467
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT03636685